Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003;2003(3):CD003293.
doi: 10.1002/14651858.CD003293.

Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma

V H C Bramwell, D Anderson, M L Charette; Sarcoma Disease Site Group

Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma

V H C Bramwell et al. Cochrane Database Syst Rev. 2003.

Abstract

Background: Considerable controversy exists as to whether any benefit of doxorubicin-based combination chemotherapy outweighs increased toxic effects, inconvenience, and additional costs, compared to single-agent doxorubicin. There is substantial variation in clinical practice in the treatment of patients with locally advanced and metastatic soft tissue sarcoma (STS).

Objectives: To determine:1) the effect, if any on response rate or survival, by using doxorubicin-based combination chemotherapy compared with single-agent doxorubicin for the treatment of patients with incurable locally advanced or metastatic STS2)if combination chemotherapy is associated with increased adverse effects compared with single-agent doxorubicin in this setting.

Search strategy: We searched CENTRAL (Cochrane Library, issue 4, 2002), MEDLINE (1966 to October 2002), CANCER LIT (1975 to October 2002), reference lists, the Physician Data Query (PDQ) clinical trials database, and the American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings (1995 to 2002).

Selection criteria: Randomized controlled trials (RCTs) comparing single-agent doxorubicin with doxorubicin-based combination chemotherapy in adults with locally advanced or metastatic STS requiring palliative chemotherapy. Abstracts and full reports published in English were eligible.

Data collection and analysis: Data were abstracted and assessed by two reviewers. Response and survival data were pooled. Data on adverse effects was tabulated.

Main results: Data on 2281 participants from eight RCTs were available from reports of single-agent doxorubicin versus doxorubicin-based combination chemotherapy. Meta-analysis using the fixed effect model detected a higher tumour response rate with combination chemotherapy compared with single-agent chemotherapy (odds ratio [OR= 1.29; 95% confidence interval [CI], 1.03 to 1.60; p = 0.03), but the OR from a pooled analysis using the random effects model and the same data did not achieve statistical significance (OR= 1.26; 95% CI, 0.96 to 1.67; p = 0.10). No significant difference between the two regimens was detected in the pooled one-year mortality rate (OR = 0.87; 95% CI, 0.73 to 1.05; p=0.14) or two-year mortality rate (OR = 0.84; 95% CI, 0.67 to 1.06; p=0.13) (N=2097). Although reporting of adverse effects was limited and inconsistent among trials (making pooling of data for this outcome impossible), adverse effects such as nausea/vomiting and hematologic toxic effects were consistently reported as being worse with combination chemotherapy across the eight eligible studies.

Reviewer's conclusions: Compared to single-agent doxorubicin, the combination chemotherapy regimens evaluated, given in conventional doses, produced only marginal increases in response rates, at the expense of increased toxic effects and with no improvements in overall survival.

PubMed Disclaimer

Conflict of interest statement

Members of the Sarcoma Disease Site Group were asked to disclose potential conflict of interest related to this systematic review. There was no known conflict of interest.

Figures

1.1
1.1. Analysis
Comparison 1 Single‐agent doxorubicin vs. doxorubicin‐based combination chemotherapy, Outcome 1 Objective tumour response (complete or partial).
1.2
1.2. Analysis
Comparison 1 Single‐agent doxorubicin vs. doxorubicin‐based combination chemotherapy, Outcome 2 Death at one year.
1.3
1.3. Analysis
Comparison 1 Single‐agent doxorubicin vs. doxorubicin‐based combination chemotherapy, Outcome 3 Death at two years.
See this image and copyright information in PMC

References

References to studies included in this review

Borden 1987 {published data only}
    1. Borden EC, Amato DA, Rosenbaum C, Enterline HT, Shiraki MJ, Creech RH, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. Journal of Clinical Oncology 1987;5:840‐50. - PubMed
Borden 1990 {published data only}
    1. Borden EC, Amato DA, Edmonson JH, Ritch PS, Shiraki M. Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft tissue sarcomas. Cancer 1990;66:862‐7. - PubMed
Chang 1976 {published data only}
    1. Chang P, Wiernik PH. Combination chemotherapy with adriamycin and streptozotocin. I. Clinical results in patients with advanced sarcoma. Clinical Pharmacology and Therapeutics 1976;20:605‐10. - PubMed
Edmonson 1993 {published data only}
    1. Edmonson JH, Ryan LM, Blum RH, Brooks JSJ, Shiraki M, Frytak S, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. Journal of Clinical Oncology 1993;11:1269‐75. - PubMed
Muss 1985 {published data only}
    1. Muss MB, Bundy B, DiSaia J, Homesley HD, Fowler WC, Creasman W, et al. Treatment of recurrent or advanced uterine sarcoma: A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer 1985;55:1648‐53. - PubMed
Omura 1983 {published data only}
    1. Omura GA, Major FJ, Blessing JA, Sedlacek TV, Thigpen JT, Creasman WT, et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 1983;52:626‐32. - PubMed
Santoro 1995 {published data only}
    1. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first‐line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Journal of Clinical Oncology 1995;13:1537‐45. - PubMed
Schoenfeld 1982 {published data only}
    1. Schoenfeld DA, Rosenbaum C, Horton J, Wolter JM, Falkson G, DeConti RC. A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin‐d and cyclophosphamide for advanced sarcoma. Cancer 1982;50:2757‐62. - PubMed

Additional references

Antman 1989
    1. Antman KH, Ryan L, Elias A, Sherman D, Grier HE. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. Journal of Clinical Oncology 1989;7:126‐31. - PubMed
Antman 1993
    1. Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, et al. An Intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. Journal of Clinical Oncology 1993;11:1276‐85. - PubMed
Bramwell 1987
    1. Bramwell VHC, Mouridsen HT, Santoro A, Blackledge G, Somers R, Verwey J, et al. Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas. European Journal of Cancer & Clinical Oncology 1987;23:311‐21. - PubMed
Bramwell 1991
    1. Bramwell VH. Chemotherapy for metastatic soft tissue sarcomas ‐ another full circle?. British Journal of Cancer 1991;64:7‐9. - PMC - PubMed
Buesa 1991
    1. Buesa JM, Mouridsen HT, Oosterom AT, Verweij J, Wagener T, Steward W, et al. High dose DTIC in advanced soft tissue sarcomas in the adult. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Annals of Oncology 1991;2:307‐9. - PubMed
Demetri 1995
    1. Demetri GD, Elias AD. Results of single agent and combination chemotherapy for advanced soft tissue sarcomas: implications for decision making in the clinic. Hematology/oncology clinics of North America 1995;9:765‐85. - PubMed
DerSimonian 1986
    1. DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled clinical trials 1986;7:177‐88. - PubMed
Enzinger 1995
    1. Enzinger FM, Weiss SW. Soft Tissue Tumours. Third Edition. St. Louis, USA: Mosby, 1995.
Figueredo 2000
    1. Figueredo A, Bramwell VHC, Bell R, Davis AM, Charette M and the members of the Cancer Care Ontario Practice Guidelines Initiative Sarcoma Disease Site Group. Adjuvant chemotherapy following complete resection of soft tissue sarcoma. Data on file. - PMC - PubMed
Pinedo 1977
    1. Pinedo HM, Kenis Y. Chemotherapy of advanced soft‐tissue sarcomas in adults. Cancer treatment reviews 1977;4:67‐86. - PubMed
SMAC 1997
    1. Sarcoma Meta‐analysis Collaboration. Adjuvant chemotherapy for localised resectable soft‐tissue sarcoma of adults: meta‐analysis of individual data. The Lancet 1997;350(9092):1647‐54. - PubMed
Spielmann 1988
    1. Spielmann M, Sevin D, Chevalier T, Subirana R, Contesso G, Genin J, et al. Second line treatment in advanced sarcomas with vindesine (VDS) and cisplatin (DDP) by continuous infusion (CI) [abstract]. Proceedings of the American Society of Clinical Oncology 1988;7:276. Abstract 1072.
Stuart‐Harris 1983
    1. Stuart‐Harris RC, Harper PG, Parsons CA, Kaye SB, Mooney CA, Gowing NF, et al. High dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft tissue sarcoma. Cancer Chemotherapy & Pharmacology 1983;11:69‐72. - PubMed
van Glabbeke 1999
    1. Glabbeke M, Oosterom A, Oosterhuis J, Mouridsen H, Crowther D, Somers R, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2,185 patients treated with anthracycline‐containing first‐line regimens ‐ a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. Journal of Clinical Oncology 1999;17:150‐7. - PubMed
Yap 1981
    1. Yap B‐S, Benjamin RS, Burgess MA, Murphy WK, Sinkovics JG, Bodey GP. A phase II evaluation of methyl CCNU and actinomycin D in the treatment of advanced sarcomas in adults. Cancer 1981;47:2807‐9. - PubMed

References to other published versions of this review

Bramwell 2000
    1. Bramwell VHC, Anderson D, Charette ML. Doxorubicin‐based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft‐tissue sarcoma: a meta‐analysis and clinical practice guideline. Sarcoma 2000;4(3):103‐12. - PMC - PubMed

Publication types